Association between polymorphism of the hepatic uptake transporter SLCO1B1 and reduced atrovastatin response (2009)
- Authors:
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; DOREA, EGIDIO LIMA - HU ; BERNIK, MARCIA MARTINS SILVEIRA - HU ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: FCF; HU
- Assunto: LIPOPROTEÍNAS LDL
- Language: Inglês
- Imprenta:
- Publisher: American Association for Clinical Chemistry
- Publisher place: Washington
- Date published: 2009
- Source:
- Título: Clinical Chemistry
- ISSN: 1530-8561
- Volume/Número/Paginação/Ano: v. 55, n. 6 suppl., p. A87 res. B-120, 2009
- Conference titles: Annual Meeting of the American Association for Clinical Chemistry
-
ABNT
RODRIGUES, Alice Cristina et al. Association between polymorphism of the hepatic uptake transporter SLCO1B1 and reduced atrovastatin response. Clinical Chemistry. Washington: American Association for Clinical Chemistry. . Acesso em: 03 mar. 2026. , 2009 -
APA
Rodrigues, A. C., Perin, P. M., Purim, S., Genvigir, F. D. V., Willrich, M. A. V., Arazi, S. S., et al. (2009). Association between polymorphism of the hepatic uptake transporter SLCO1B1 and reduced atrovastatin response. Clinical Chemistry. Washington: American Association for Clinical Chemistry. -
NLM
Rodrigues AC, Perin PM, Purim S, Genvigir FDV, Willrich MAV, Arazi SS, Hirata MH, Dórea EL, Bernik MMS, Hirata RDC. Association between polymorphism of the hepatic uptake transporter SLCO1B1 and reduced atrovastatin response. Clinical Chemistry. 2009 ; 55( 6 suppl.): A87 res. B-120.[citado 2026 mar. 03 ] -
Vancouver
Rodrigues AC, Perin PM, Purim S, Genvigir FDV, Willrich MAV, Arazi SS, Hirata MH, Dórea EL, Bernik MMS, Hirata RDC. Association between polymorphism of the hepatic uptake transporter SLCO1B1 and reduced atrovastatin response. Clinical Chemistry. 2009 ; 55( 6 suppl.): A87 res. B-120.[citado 2026 mar. 03 ] - Polimorfismos no receptor scavenger classe B tipo I e sua relação com perfil sérico e resposta a atorvastatina em indivíduos brasileiros
- Scavenger receptor class B type I polymorphisms and its relation with serum lipids profile and response to atorvastatin in Brazilian individuals
- mRNA expression of SREBF1, SREBF2 and SCAP transcription factors in peripheral mononuclear cells is modulated by atorvastatin therapy
- CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin
- Atorvastatin effects on SREBF1 and SCAP gene expression in peripheral blood mononuclear cells of hypercholesterolemic patients
- Alteration of the expression of efflux and uptake transporters during hypercholesterolemia. Role in variability of atorvastatin response
- Estudo da expressão gênica e polimorfismos da CYP3A5 em indivíduos hipercolesterolêmicos tratados com atorvastatina
- Variants in S1P and ABCG1 genes are novel independent risk factors for dyslipidemia
- Efeito da atorvastatina sobre os genes SREBF1, SREBF2 e SCAP em pacientes hipercolesterolêmicos
- Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
